PTIX RSI Chart
Last 7 days
11.1%
Last 30 days
11.1%
Last 90 days
50%
Trailing 12 Months
-27.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 | 0 |
2011 | 0 | 0 | 38.6M | 0 |
2010 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 12, 2023 | arrow alexander k. | bought | 6,480 | 0.81 | 8,000 | chief financial officer |
May 18, 2022 | arrow alexander k. | bought | 5,760 | 0.72 | 8,000 | chief financial officer |
May 17, 2022 | arrow alexander k. | bought | 16,330 | 0.71 | 23,000 | chief financial officer |
May 03, 2021 | barrage khalil | acquired | 532,500 | 1.47917 | 360,000 | - |
Apr 30, 2021 | arrow alexander k. | bought | 2,290 | 2.29 | 1,000 | chief financial officer |
Apr 29, 2021 | arrow alexander k. | bought | 2,290 | 2.29 | 1,000 | chief financial officer |
Which funds bought or sold PTIX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | 11,326 | 24,033 | -% |
May 15, 2024 | MORGAN STANLEY | unchanged | - | 1.00 | 2.00 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | 1.00 | 2.00 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -35.6 | 1,237 | 10,173 | -% |
May 15, 2024 | GTS SECURITIES LLC | added | 0.79 | 638 | 1,016 | -% |
May 13, 2024 | UBS Group AG | sold off | -100 | -1.00 | - | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | reduced | -0.1 | 20,636 | 43,834 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 3.85 | 21.00 | 47.00 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | new | - | 37,474 | 37,474 | -% |
May 10, 2024 | VANGUARD GROUP INC | unchanged | - | 25,207 | 58,041 | -% |
Unveiling Protagenic Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Protagenic Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Protagenic Therapeutics, Inc. News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 | 2022Q4 | 2011Q3 | 2011Q2 | 2010Q3 | 2010Q2 |
Revenue | - | - | - | - | - | 12,326,000 | 6,270,000 | 9,177,000 | 10,813,000 |
Costs and Expenses | - | - | - | - | - | 17,344,000 | 11,293,000 | 12,845,000 | 15,301,000 |
Operating Expenses | 43.4% | 1,738,359 | 1,212,226 | 739,294 | 655,778 | - | - | - | - |
S&GA Expenses | -100.0% | - | 200,799 | 391,263 | 398,258 | - | - | - | - |
R&D Expenses | 44.4% | 1,460,746 | 1,011,427 | 348,031 | 257,520 | - | - | - | - |
EBITDA Margin | -21.3% | -0.15 | -0.13 | -0.07 | -0.09 | - | - | - | - |
Interest Expenses | -100.0% | - | 12,852 | 31,263 | 31,958 | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -2.9% | -1,724,294 | -1,676,184 | -718,096 | -601,374 | - | - | - | - |
EBT Margin | -20.1% | -0.16 | -0.13 | -0.08 | -0.09 | - | - | - | - |
Net Income | -2.9% | -1,724,294 | -1,676,184 | -718,096 | -601,374 | - | - | - | - |
Net Income Margin | -20.1% | -0.16 | -0.13 | -0.08 | -0.09 | - | - | - | - |
Free Cashflow | -45.0% | -1,659,185 | -1,144,434 | -371,834 | -180,936 | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -40.4% | 2,579 | 4,323 | 5,433 | 6,919 | 7,666 | 8,037 | 8,254 | 9,015 | 9,798 | 11,060 | 11,657 | 12,062 | 6,471 | 879 | 1,002 | 1,188 | 786 | 842 | 287 | 350 | 465 |
Current Assets | -41.2% | 2,468 | 4,200 | 5,377 | 6,918 | 7,665 | 8,036 | 8,254 | 9,015 | 9,798 | 11,060 | 11,657 | 12,062 | 196 | 879 | 1,002 | 1,188 | 786 | 842 | 287 | 349 | 464 |
Cash Equivalents | -100.0% | - | 1,288 | 153 | 219 | 138 | 215 | 158 | 339 | 482 | 541 | 460 | 11,933 | 192 | 671 | 989 | 1,181 | 754 | 799 | 277 | 340 | 419 |
Net PPE | -10.2% | 111 | 123 | 56.00 | 2.00 | 2.00 | 2.00 | - | - | - | - | - | - | - | - | 35* | 117* | 191* | 296* | 374* | 463* | 540* |
Liabilities | -31.9% | 446 | 655 | 1,280 | 1,505 | 1,252 | 1,120 | 872 | 756 | 1,079 | 1,118 | 1,287 | 1,264 | 2,179 | 2,029 | 2,023 | 1,934 | 1,372 | 1,477 | 1,334 | 1,192 | 1,050 |
Current Liabilities | -31.9% | 446 | 655 | 1,280 | 1,505 | 1,252 | 1,120 | 553 | 463 | 784 | 800 | 724 | 603 | 651 | 655 | 712 | 800 | 824 | 1,197 | 651 | 729 | 827 |
Shareholder's Equity | -41.9% | 2,132 | 3,668 | 4,153 | 5,414 | 6,414 | 6,918 | 7,382 | 8,258 | 8,720 | 9,942 | 10,371 | 10,798 | - | - | - | - | - | - | - | - | - |
Retained Earnings | -5.6% | -32,502 | -30,777 | -29,101 | -27,705 | -26,495 | -25,777 | -25,176 | -24,250 | -23,583 | -22,221 | -21,331 | -20,453 | -18,905 | -17,698 | -17,175 | -16,216 | -15,648 | -15,150 | -14,400 | -14,277 | -13,998 |
Additional Paid-In Capital | 0.5% | 34,721 | 34,559 | 33,872 | 33,705 | 33,538 | 33,371 | 33,171 | 32,957 | 32,701 | 32,412 | 31,873 | 31,420 | 17,093 | 16,720 | 16,326 | 15,643 | 15,237 | 14,687 | 14,209 | 14,070 | 13,809 |
Shares Outstanding | 0% | 4,435 | 4,435 | 4,331 | 4,331 | 4,331 | 4,321 | 4,321 | 4,320 | 4,308 | 4,302 | 3,485 | 3,622 | 2,630 | 2,590 | - | - | - | - | - | - | - |
Float | - | - | - | - | 8,792 | - | - | - | 12,515 | - | - | - | - | 66,316 | - | - | 12,006 | - | - | - | 15,392 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -45.0% | -1,659 | -1,144 | -655 | -1,531 | -371 | -180 | -535 | -847 | -430 | -405 | -1,075 | -710 | -607 | -320 | -517 | -145 | -364 | -149 | -61.76 | -80.79 | -196 |
Share Based Compensation | -2.9% | 162 | 167 | 167 | 167 | 167 | 199 | 215 | 216 | 236 | 218 | 232 | 723 | 346 | 412 | 492 | 391 | 360 | -53.01 | 139 | 261 | 451 |
Cashflow From Investing | -47.2% | 1,203 | 2,278 | 591 | 1,612 | 295 | 162 | 358 | 707 | 371 | 486 | - | - | - | - | - | - | - | - | - | - | 250 |
Cashflow From Financing | - | - | - | - | - | - | - | - | - | - | - | - | 12,451 | 127 | - | 323 | 570 | 330 | - | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
OPERATING AND ADMINISTRATIVE EXPENSES | ||
Research and development | $ 1,460,746 | $ 348,031 |
General and administrative | 277,613 | 391,263 |
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES | 1,738,359 | 739,294 |
LOSS FROM OPERATIONS | (1,738,359) | (739,294) |
OTHER INCOME | ||
Interest income | 13,867 | 56,893 |
Interest expense | (31,263) | |
Realized gain (loss) on marketable securities | 198 | (4,432) |
TOTAL OTHER INCOME | 14,065 | 21,198 |
LOSS BEFORE TAX | (1,724,294) | (718,096) |
INCOME TAX EXPENSE | ||
NET LOSS | (1,724,294) | (718,096) |
Other Comprehensive Loss - net of tax | ||
Net unrealized gain on marketable securities | 26,587 | 47,677 |
Foreign exchange translation income | 192 | 467 |
TOTAL COMPREHENSIVE LOSS | $ (1,697,515) | $ (669,952) |
Net loss per common share - Basic | $ (0.39) | $ (0.17) |
Net loss per common share - Diluted | $ (0.39) | $ (0.17) |
Weighted average common shares - Basic | 4,435,132 | 4,317,875 |
Weighted average common shares - Diluted | 4,435,132 | 4,317,875 |
Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash | $ 831,778 | $ 1,287,893 |
Marketable securities | 1,592,025 | 2,768,119 |
Prepaid expenses | 43,994 | 144,025 |
TOTAL CURRENT ASSETS | 2,467,797 | 4,200,037 |
Equipment - net | 110,761 | 123,332 |
TOTAL ASSETS | 2,578,558 | 4,323,369 |
CURRENT LIABILITIES | ||
TOTAL CURRENT LIABILITIES | 446,095 | 655,252 |
TOTAL LIABILITIES | 446,095 | 655,252 |
STOCKHOLDERS’ EQUITY | ||
Common stock, $0.0001 par value, 100,000,000 shares authorized, 4,435,132 and 4,435,132 shares issued and outstanding at March 31, 2024, and December 31, 2023 | 444 | 444 |
Additional paid-in-capital | 34,720,952 | 34,559,091 |
Accumulated deficit | (32,502,166) | (30,777,872) |
Accumulated other comprehensive loss | (86,767) | (113,546) |
TOTAL STOCKHOLDERS’ EQUITY | 2,132,463 | 3,668,117 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 2,578,558 | 4,323,369 |
Preferred Stock [Member] | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock, value | ||
Series B Convertible Preferred Stock [Member] | ||
STOCKHOLDERS’ EQUITY | ||
Preferred stock, value | ||
Nonrelated Party [Member] | ||
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 365,686 | 439,757 |
Related Party [Member] | ||
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | $ 80,409 | $ 215,495 |